Company profile for NAYA Therapeutics

NAYA Therapeutics

NEW Drugs in Dev: 3

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

pharmacompass-2-2026-02-09

Contact Supplier

VIRTUAL BOOTH
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

8 News #PharmaBuzz

media
8 News #PharmaBuzz

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NAYA Therapeutics is a clinical-stage biopharmaceutical company pioneering next-generation bifunctional antibodies to transform oncology care. Our proprietary plug-and-play antibody platform enhances avidity and creates a targeted synapse effect for precise tumor elimination. Focused on HCC and Multiple Myeloma, our lead asset, NY-303 (GPC3×NKp46), targets immunotherapy-resistant HCC patients (70-85% of treatable cases), with...

NAYA Therapeutics is a clinical-stage biopharmaceutical company pioneering next-generation bifunctional antibodies to transform oncology care. Our proprietary plug-and-play antibody platform enhances avidity and creates a targeted synapse effect for precise tumor elimination. Focused on HCC and Multiple Myeloma, our lead asset, NY-303 (GPC3×NKp46), targets immunotherapy-resistant HCC patients (70-85% of treatable cases), with Phase I/IIa trials initiating H2 2025. We are expanding a pipeline of highly differentiated therapies to address unmet needs in solid and hematologic malignancies.

Clinical OutsourcingClinical Outsourcing

Not Confirmed

Not Confirmed

03-04 March, 2026

Copthorne Tara Hotel, London Kensington, United Ki
Natural Product Expo W...Natural Product Expo West

Not Confirmed

Not Confirmed

03-06 March, 2026

California, U.S.A
Natural Products ExpoNatural Products Expo

Not Confirmed

Not Confirmed

03-06 March, 2026

California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

United_States_of_America Flag

Country

Country

U.S.A

Address

Address

1200 Brickell Avenue, Suite 1960 Miami, FL, 33131

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.nayatx.com/

Linkedin

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

NAYA Therapeutics Names Jason D. Hurt as Chief Medical Officer

17 Feb 2026

// PHARMIWEB

NAYA Therapeutics Opens Hub at Paris-Saclay Cancer Institute

07 Jan 2026

// PHARMIWEB

NAYA Therapeutics To Present At NOAR Europe Annual Meeting

04 Nov 2025

// PHARMIWEB

NAYA Partners Alpha Nuclide For Gpc3 Astatine-211 Therapy

13 Oct 2025

// ACCESSWIRE

Naya Therapeutics Partners Atley Solutions for Astatine-211

02 Sep 2025

// PHARMAWEB

NAYA and IONETIX to Build US Network for Astatine-211 Therapies

21 Aug 2025

// ACCESSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search